WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today confirmed that the American Heart Association (AHA) and American College of Cardiology (ACC) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes (NSTE-ACS). The guideline supports differentiation among currently available P2Y12 inhibitors, including ticagrelor, clopidogrel, and prasugrel, for these patients. BRILINTA is now preferred over clopidogrel for the management of NSTE-ACS patients who undergo an early invasive (angiography with intent for PCI if appropriate) or ischemia-guided strategy (i.e., medically managed), or those who receive a coronary stent. This is the first time the AHA and ACC have recommended one P2Y12 over another in the treatment of acute coronary syndrome (ACS).
Help employers find you! Check out all the jobs and post your resume.
